Staphylococcus aureus: bacteriophage and uses thereof
AssigneeIntralytix, Inc.
InventorsGary R. Pasternack, Alexander Sulakvelidze
Life of this patent
Estimating the term…
Abstract
The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.
Claims6
An isolated bacteriophage SAML-4, SAML-150, or SATA-8505 said bacteriophages having been deposited under ATCC accession Nos. PTA-9474, PTA-9475, and PTA-9476, respectively, wherein said bacteriophage has lytic activity against Staphylococcus aureus strains.
Isolated progeny of the bacteriophage SAML-4 SAML-150, or SATA-8505, wherein said progeny of said bacteriophage have the same phenotypic characteristics and same lytic activity against Staphylococcus aureus strains as said bacteriophage, and said strains having been deposited under ATCC accession Nos. PTA-9474, PTA-9475, and PTA-9476, respectively.
Dependencies are inferred from the claim text.